Single-arm open-label pilot trial of Pau d'Arco (Tabebuia bark) on primary dysmenorrhoea in reproductive-age women
Primary Dysmenorrhea
Enrolment: 12 · Results not recorded
Loading the evidence…
Nutraceutical · Crude botanical extract; no ChEMBL entity. Only registered Tabebuia trial uses Pau d'Arco, i.e. Handroanthus/Tabebuia impetiginosus bark, a different species, so this is genus-level evidence only.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Primary Dysmenorrhea
Enrolment: 12 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Intraplantar inoculation of Bothrops mattogrossensis venom, with a maximum hyperalgesic dose of 3 micrograms per paw
Oral extract at 720 mg/kg reduced venom-induced hyperalgesia without motor impairment and lowered inflammatory infiltrate and ATF-3 expression from 35.4% to 25.9%.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.